Lord's Mark Industries Limited reported a standalone net profit of ₹32.16 crore for the quarter ended June 30, 2026, marking a significant turnaround from the ₹0.03 crore loss recorded in Q1FY25. The company’s consolidated net profit for the period was ₹33.18 crore, up from a ₹0.03 crore loss in the corresponding quarter of the previous year.

Standalone revenue from operations declined 36.6% quarter-on-quarter (QoQ) to ₹280.36 crore, down from ₹441.98 crore in Q4FY25. Consolidated revenue from operations also contracted 37.3% QoQ to ₹307.68 crore, compared to ₹491.17 crore in the prior quarter.

Financial Performance

The Board of Directors approved the unaudited financial results at its meeting held on August 13, 2026. The results were reviewed by the Audit Committee and limited reviewed by statutory auditors Sanjeev S Gupta & Associates.

What the Numbers Show

Despite the decline in top-line revenue, Lord's Mark Industries improved its profitability margins significantly compared to the previous year. While standalone revenue fell 36.6% QoQ, the company managed to reduce total expenses by 37.6% QoQ to ₹241.30 crore. This cost discipline allowed the firm to post a profit before tax of ₹43.92 crore, contrasting sharply with the ₹0.03 crore loss in Q1FY25.

Balance Sheet and Cash Flow

As of June 30, 2026, the standalone balance sheet showed total assets of ₹1,380.16 crore, an increase from ₹1,305.88 crore at the end of FY25. Current assets rose to ₹959.37 crore, driven largely by short-term loans and advances which jumped to ₹307.96 crore from ₹66.97 crore in March 2026. Trade receivables declined to ₹394.75 crore from ₹562.00 crore.

Consolidated total assets stood at ₹1,491.55 crore, up from ₹1,443.02 crore. Long-term borrowings decreased slightly to ₹138.88 crore from ₹145.84 crore, while short-term borrowings fell to ₹218.91 crore from ₹238.34 crore.

Corporate Developments

The financial statements reflect the amalgamation of Lord's Mark Industries Limited with Kratos Energy & Infrastructure Limited, pursuant to an order passed by the NCLT Mumbai. The resultant entity continues to operate under the name Lord's Mark Industries Limited. The consolidated accounts include four subsidiaries: Lords Mark Tech Next Private Limited, Lords Green Energy Private Limited, Renalyx Health Systems Private Limited, and Lords Mark Micro Biotech Private Limited.

Lords Mark Industries Limited has secured a manufacturing license for its Biomesca Analytics Platform, becoming the first and only company in India to receive such approval for an In Vitro Diagnostic Software (Software as a Medical Device – SaMD). The license, granted under the Medical Devices Rules, 2017, positions the platform as a wellness and health-information tool designed for preventive healthcare and early health risk assessment. This regulatory milestone enables the company to commercialize gut microbiome science for mainstream wellness applications.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing, dated August 10, 2026, was submitted to the Manager – Listing Department at BSE Limited. The company, listed under Scrip code 501261, highlighted that the approval marks a significant step in integrating genomics with nutrition for personalized health insights.

Platform Capabilities and Classification

The Biomesca Analytics Platform combines whole metagenome sequencing data with a validated bioinformatics pipeline. It generates detailed gut microbiome profiles, including diversity scores, enterotype classification, and functional metabolic assessments. Based on these metrics, the platform provides evidence-based personalized dietary recommendations. The license classifies the software specifically for preventive healthcare purposes rather than diagnostic treatment.

Strategic Expansion Plans

Following the license receipt, Lord's Mark Industries plans to establish a nationwide network of Health & Wellness Centres. These centres will be set up in collaboration with hospitals, doctors, and healthcare institutions. The objective is to provide personalized microbiome assessments and preventive care strategies to a broader consumer base. The company aims to make these preventive healthcare solutions accessible, affordable, and impactful for millions of individuals across India.

Management Commentary

Sachidanand Upadhyay, Managing Director of Lord's Mark Industries Ltd., stated that healthcare is shifting from reactive treatment to proactive prevention. He emphasized that Biomesca represents a new era where genomics and nutrition converge to create truly personalized wellness. Through partnerships with medical professionals, the company intends to empower individuals with scientific health insights before disease develops.

What This Means for Investors

The receipt of the manufacturing license validates the technical and regulatory readiness of the Biomesca platform. As the first Indian entity to secure this specific SaMD classification under the Medical Devices Rules, 2017, Lord's Mark Industries holds a unique market position in the gut microbiome analytics segment. The planned expansion into a network of Health & Wellness Centres suggests a shift towards direct-to-consumer or provider-partnered service models, potentially creating new revenue streams beyond traditional product sales.